125-58-6

Basic information

• Product Name: R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST
• Synonyms: R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST;(6r)-methadone;(r)-6-(dimethylamino)-4,4-diphenyl-3-heptanone;4-diphenyl-6-(dimethylamino)-(r)-3-hetpanon;4-diphenyl-6-(dimethylamino)-l-3-heptanon;l-6-(dimethylamino)-4,4-diphenyl-3-heptanone;levomethadone;levothyl
• CAS NO: 125-58-6
• Molecular Formula: C₂₁H₂₇NO
• Molecular Weight: 309.44518
• Mol File: 125-58-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 99°C
• Boiling Point: 449.71°C (rough estimate)
• Flash Point: 126.5°C
• Appearance: /
• Density: 1.0350 (rough estimate)
• Vapor Pressure: 2.2E-07mmHg at 25°C
• Refractive Index: 1.5614 (estimate)
• CAS DataBase Reference: R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST(CAS DataBase Reference)
• NIST Chemistry Reference: R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST(125-58-6)
• EPA Substance Registry System: R(-)-METHADONE HYDROCHLORIDE OPIOID AGON IST(125-58-6)

Safety Data

• Hazardous Substances Data: 125-58-6(Hazardous Substances Data)

Usage

Purification Methods

This pharmacologically active (against narcotic addiction) enantiomer was obtained by optical resolution (using D-tartaric acid) of the racemate and was purified by precipitation of the hydrochloride from aqueous solution at pH >6, dried and recrystallised from propan-2-ol. The R-hydrochloride [5967-73-7], when recrystallised from propan-2-ol, has m 245-246o, [] D 20 -169o (c 2, EtOH). The S-(+)-enantiomer [5653-8-5] also recrystallises from propan-2-ol and has recorded m of 100-101o, [] D 25 + 26o (c 1.2, H2O). The S-hydrochloride [15284-15-8], when crystallised from propan-2-ol, has m 243-244o, [] D 20 +169o (c 2, EtOH). [Larsen et al. J Am Chem Soc 70 4194 1948, Brode & Hill J Org Chem 13 191 1948, Schultz et al. J Am Chem Soc 69 2454 1947, Easton et al. J Am Chem Soc 69 2941 1947, Winter & Flataker J Pharmacol Exp Ther 98 305 1950, Beilstein 14 III 278, 1 4 III/IV 300.]

InChI:InChI=1/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3/t17-/m1/s1

Upstream product

• 76-99-3 Methadone 
• 86-29-3 Diphenylacetonitrile 
• 125-79-1 (R,S)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 7576-16-1 (R)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 119-61-9 benzophenone 
• 129824-26-6 3-Dimethylamino-1,1-diphenylbut-1-en 
• 75-07-0 acetaldehyde 
• 123-38-6 propionaldehyde 
• 5967-73-7 (R)-methadone hydrochloride 

Relevant articles and documents

Simultaneous chiral separation of tramadol and methadone in tablets, human urine, and plasma by capillary electrophoresis using maltodextrin as the chiral selector

The stereoselective analysis and separation of racemic drugs play an important role in pharmaceutical industry to eliminate the unwanted isomer and find the right therapeutic control for the patient. Present study suggests a maltodextrin-modified capillary electrophoresis method for a single‐run chiral separation of two closely similar opiate pain relief drugs: tramadol (TRA) and methadone (MET). The best separation method possible for the both enantiomers was achieved on an uncoated fused‐silica capillary at 25°C using 100 mM phosphate buffer (pH 8.0) containing 20% (w v?1) maltodextrin with dextrose equivalent of 4–7 and an applied voltage of 16 kV. Under optimal conditions, the baseline resolution of TRA and MET enantiomers was obtained in less than 12 minutes. The relative standard deviations (n = 3) of 20 μg mL?1 TRA and MET were 2.28% and 3.77%, respectively. The detection limits were found to be 2 μg mL?1 for TRA and 1.5 μg mL?1 for MET. This method was successfully applied to the measurement of drugs concentration in their tablets, urine, and plasma samples.

(R)-6-(DIMETHYLAMINO)-4,4-DIPHENYLHEPTAN-3-ONE

(R)-6-(dimethylamino)-4,4-diphenylheptan-3-one and a process to produce thereof.

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.